WilmerHale Represents Underwriters in $258.75M Public Offering of Kymera Therapeutics

WilmerHale Represents Underwriters in $258.75M Public Offering of Kymera Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 2,830,533 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 828,220 additional shares of common stock, and pre-funded warrants to purchase 3,519,159 shares of common stock by Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera received approximately $258.75 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on August 19, 2024 and closed on August 21, 2024.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer, Matt Kosior and Michaela Rosen with assistance from Barish Ozdamar on intellectual property matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel